Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.
Li Z, McGinn O, Wu Y, Bahreini A, Priedigkeit NM, Ding K, Onkar S, Lampenfeld C, Sartorius CA, Miller L, Rosenzweig M, Cohen O, Wagle N, Richer JK, Muller WJ, Buluwela L, Ali S, Bruno TC, Vignali DAA, Fang Y, Zhu L, Tseng GC, Gertz J, Atkinson JM, Lee AV, Oesterreich S. Li Z, et al. Among authors: muller wj. Nat Commun. 2022 Apr 19;13(1):2011. doi: 10.1038/s41467-022-29498-9. Nat Commun. 2022. PMID: 35440136 Free PMC article.
ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer.
Deblois G, Smith HW, Tam IS, Gravel SP, Caron M, Savage P, Labbé DP, Bégin LR, Tremblay ML, Park M, Bourque G, St-Pierre J, Muller WJ, Giguère V. Deblois G, et al. Among authors: muller wj. Nat Commun. 2016 Jul 12;7:12156. doi: 10.1038/ncomms12156. Nat Commun. 2016. PMID: 27402251 Free PMC article.
An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.
Smith HW, Hirukawa A, Sanguin-Gendreau V, Nandi I, Dufour CR, Zuo D, Tandoc K, Leibovitch M, Singh S, Rennhack JP, Swiatnicki M, Lavoie C, Papavasiliou V, Temps C, Carragher NO, Unciti-Broceta A, Savage P, Basik M, van Hoef V, Larsson O, Cooper CL, Vargas Calderon AC, Beith J, Millar E, Selinger C, Giguère V, Park M, Harris LN, Varadan V, Andrechek ER, O'Toole SA, Topisirovic I, Muller WJ. Smith HW, et al. Among authors: muller wj. Nat Commun. 2019 Jul 1;10(1):2901. doi: 10.1038/s41467-019-10681-4. Nat Commun. 2019. PMID: 31263101 Free PMC article.
Targeting fatty acid oxidation enhances response to HER2-targeted therapy.
Nandi I, Ji L, Smith HW, Avizonis D, Papavasiliou V, Lavoie C, Pacis A, Attalla S, Sanguin-Gendreau V, Muller WJ. Nandi I, et al. Among authors: muller wj. Nat Commun. 2024 Aug 3;15(1):6587. doi: 10.1038/s41467-024-50998-3. Nat Commun. 2024. PMID: 39097623 Free PMC article.
Osteopontin is a therapeutic target that drives breast cancer recurrence.
Gu Y, Taifour T, Bui T, Zuo D, Pacis A, Poirier A, Attalla S, Fortier AM, Sanguin-Gendreau V, Pan TC, Papavasiliou V, Lin NU, Hughes ME, Smith K, Park M, Tremblay ML, Chodosh LA, Jeselsohn R, Muller WJ. Gu Y, et al. Among authors: muller wj. Nat Commun. 2024 Oct 24;15(1):9174. doi: 10.1038/s41467-024-53023-9. Nat Commun. 2024. PMID: 39448577 Free PMC article.
386 results